Issue
Copyright (c) 2026 Pouria Salajegheh , Amirali Salajegheh , Farzaneh Yazdi

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.Gene polymorphism and serum level of RANKL among patients with rheumatoid arthritis: a systematic review and meta-analysis
Corresponding Author(s) : Farzaneh Yazdi
Cellular and Molecular Biology,
Vol. 72 No. 3: Issue 3
Abstract
Receptor activator of nuclear factor-κB ligand (RANKL) is a key mediator linking inflammation to osteoclast activation and bone erosion in rheumatoid arthritis (RA). Evidence on circulating RANKL levels and RANKL (TNFSF11) polymorphisms in RA has been inconsistent. Web of Science, Scopus, and PubMed were searched from inception to December 2025 for clinical studies comparing patients with RA and healthy controls and reporting either serum/plasma RANKL concentrations and/or RANKL genotype/allele distributions. Mean differences (MD) were pooled for circulating RANKL, and odds ratios (OR) were pooled for polymorphisms under allelic, dominant, and recessive models. Ten studies (908 RA; 525 controls) were included for serum RANKL. Serum RANKL was higher in RA than controls (pooled MD 8.16, 95% CI 3.90–12.41). For genetic analyses, three SNPs were eligible for pooling. rs9533156 showed a significant association with RA in the allelic (C vs T: OR 0.82, 95% CI 0.70–0.97) and dominant models (CC+CT vs TT: OR 0.77, 95% CI 0.61–0.98). rs2277438 showed a borderline allelic association (OR 1.21, 95% CI 1.00–1.45) and model-dependent results for the recessive contrast with heterogeneity. RA is associated with increased circulating RANKL, while genetic associations appear SNP-specific, with the most consistent evidence observed for rs9533156. Larger, multi-ethnic studies with standardized biomarker measurements are needed.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX